Shockwave Medical, Inc. v. Cardiovascular Systems, Inc.

Plain English (For Everyone)

Imagine you invented a new type of medical device and patented it. If someone else starts selling a similar device, you might sue them to stop them. However, to get a court order to stop them immediately while the lawsuit proceeds (a preliminary injunction), you usually have to show you're likely to win and that you'll be harmed if they continue selling. In this case, the court said the inventor didn't show they were likely to win because their patent might have been based on something already known, and they didn't prove they'd suffer significant harm if the other company kept selling their device. So, the court refused to stop the other company for now.

For Legal Practitioners

The Federal Circuit affirmed the denial of a preliminary injunction, emphasizing that a strong showing of likelihood of success on the merits is paramount. Here, the court found the asserted patent claims likely invalid due to anticipation by prior art, a critical factor in denying the injunction. The failure to demonstrate irreparable harm and a favorable balance of hardships further solidified the denial. Practitioners should note the court's rigorous scrutiny of patent validity at the preliminary injunction stage, even when faced with a potentially infringing product.

For Law Students

This case tests the standard for granting a preliminary injunction in patent infringement cases, specifically the likelihood of success on the merits. The Federal Circuit's affirmance highlights that a patent's validity, particularly if challenged by anticipation from prior art, is a central consideration. This aligns with the doctrine that injunctive relief requires a strong showing of probable success, not just a possibility of infringement. Students should recognize the interplay between patent validity challenges and the equitable factors for injunctive relief.

Newsroom Summary

A medical device company, Shockwave Medical, failed to get a court order to immediately stop a competitor, Cardiovascular Systems, from selling its product. The appeals court agreed that Shockwave didn't show it was likely to win its patent infringement case, partly because the competitor presented evidence that Shockwave's patent might not be new. This means the competitor can continue selling its device while the lawsuit continues.

Constitutional Issues

Patent eligibility under 35 U.S.C. § 101

Rule Statements

Claims that are not directed to an abstract idea, law of nature, or natural phenomenon, and that recite specific improvements to technology or practical applications of scientific principles, are eligible for patent protection.

The focus of the § 101 inquiry is on whether the claim as a whole is directed to a patent-ineligible concept, not on whether individual elements of the claim might be considered generic or conventional.

Judges

• Richard G. Taranto

Scenario: You are a small business owner who has developed a unique product and obtained a patent. A larger competitor begins selling a very similar product. You want to stop them immediately while you pursue a full lawsuit, but the court denies your request for an immediate halt.

Your Rights: You have the right to pursue a full patent infringement lawsuit to determine validity and seek damages. However, you do not automatically have the right to an immediate injunction stopping the competitor's sales unless you can demonstrate a strong likelihood of winning your case and suffering irreparable harm.

What To Do: Consult with a patent attorney to assess the strength of your patent against the competitor's prior art arguments. Gather evidence of lost sales, market share erosion, and damage to your reputation that would constitute irreparable harm. Prepare to vigorously litigate the patent's validity and infringement in the district court.

Is it legal for a competitor to sell a product that is similar to mine if my patent might be invalid?

It depends. If your patent is indeed invalid (e.g., because the invention wasn't new and was disclosed in prior art), then the competitor's product may not be infringing your patent, and selling it would be legal. However, if your patent is ultimately found valid and their product infringes, then selling it would be illegal.

This ruling applies to patent law in the United States, specifically interpreting the standards for preliminary injunctions under federal patent law.

For Patent Holders

Patent holders seeking preliminary injunctions must be prepared to rigorously defend their patent's validity against prior art challenges early in litigation. Simply showing a likelihood of infringement may not be enough if the patent's novelty or non-obviousness is seriously questioned.

For Competitors accused of patent infringement

Companies accused of infringement may find it easier to avoid preliminary injunctions if they can present credible prior art that casts doubt on the validity of the asserted patent claims. This can allow them to continue sales while the validity dispute is fully litigated.

Q: What is Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. about?

Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. is a case decided by Federal Circuit on July 14, 2025.

Q: What court decided Shockwave Medical, Inc. v. Cardiovascular Systems, Inc.?

Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. decided?

Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. was decided on July 14, 2025.

Q: What is the citation for Shockwave Medical, Inc. v. Cardiovascular Systems, Inc.?

The citation for Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. is 142 F.4th 1371. Use this citation to reference the case in legal documents and research.

Q: What is the full case name and what court decided it?

The case is Shockwave Medical, Inc. v. Cardiovascular Systems, Inc., and it was decided by the United States Court of Appeals for the Federal Circuit (CAFC). The CAFC reviewed a decision from a lower court regarding a preliminary injunction.

Q: Who are the parties involved in the Shockwave Medical v. Cardiovascular Systems case?

The parties are Shockwave Medical, Inc., the appellant and patent holder, and Cardiovascular Systems, Inc. (CSI), the appellee and alleged infringer. Shockwave Medical sought to prevent CSI from continuing certain activities pending a final resolution of the patent dispute.

Q: What was the main issue before the Federal Circuit in Shockwave Medical v. Cardiovascular Systems?

The primary issue was whether the district court erred in denying Shockwave Medical's request for a preliminary injunction. Shockwave argued that CSI was infringing its patent and that an injunction was necessary to prevent irreparable harm.

Q: What is a preliminary injunction and why did Shockwave Medical want one?

A preliminary injunction is a court order issued early in a lawsuit to stop a party from taking certain actions that could cause irreparable harm before the case is fully decided. Shockwave Medical sought one to prevent Cardiovascular Systems, Inc. from continuing to sell its products, which Shockwave alleged infringed its patent.

Q: What was the nature of the dispute between Shockwave Medical and Cardiovascular Systems?

The dispute centered on Shockwave Medical's U.S. Patent No. 9,138,351, which allegedly covers certain intravascular lithotripsy technology. Shockwave accused Cardiovascular Systems, Inc. of infringing this patent with its own products.

Q: Is Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. published?

Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in Shockwave Medical, Inc. v. Cardiovascular Systems, Inc.?

The court ruled in favor of the defendant in Shockwave Medical, Inc. v. Cardiovascular Systems, Inc.. Key holdings: The court held that Shockwave failed to establish a likelihood of success on the merits because its asserted patent claims were likely invalid due to anticipation by the '394 patent, a prior art reference that disclosed all limitations of the claims.; Shockwave did not demonstrate a likelihood of success on the merits by showing a substantial question of patentability, as the prior art reference clearly anticipated the asserted claims.; The court held that Shockwave failed to demonstrate irreparable harm, as it did not show a sufficient causal nexus between the alleged infringement and the loss of market share or goodwill.; The court held that the balance of hardships did not tip in Shockwave's favor, noting that the potential harm to Cardiovascular Systems from an injunction outweighed the harm to Shockwave from its denial, especially given the likely invalidity of the asserted patent claims.; The court affirmed the district court's denial of a preliminary injunction, finding no abuse of discretion in its equitable balancing of the factors..

Q: Why is Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. important?

Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. has an impact score of 25/100, indicating limited broader impact. This decision reinforces the high bar for obtaining preliminary injunctions in patent cases, particularly when the validity of the asserted patent is seriously challenged by clear prior art. It highlights that a strong showing of likely patent invalidity can be fatal to a preliminary injunction request, even if other factors might otherwise favor the patent holder.

Q: What precedent does Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. set?

Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. established the following key holdings: (1) The court held that Shockwave failed to establish a likelihood of success on the merits because its asserted patent claims were likely invalid due to anticipation by the '394 patent, a prior art reference that disclosed all limitations of the claims. (2) Shockwave did not demonstrate a likelihood of success on the merits by showing a substantial question of patentability, as the prior art reference clearly anticipated the asserted claims. (3) The court held that Shockwave failed to demonstrate irreparable harm, as it did not show a sufficient causal nexus between the alleged infringement and the loss of market share or goodwill. (4) The court held that the balance of hardships did not tip in Shockwave's favor, noting that the potential harm to Cardiovascular Systems from an injunction outweighed the harm to Shockwave from its denial, especially given the likely invalidity of the asserted patent claims. (5) The court affirmed the district court's denial of a preliminary injunction, finding no abuse of discretion in its equitable balancing of the factors.

Q: What are the key holdings in Shockwave Medical, Inc. v. Cardiovascular Systems, Inc.?

1. The court held that Shockwave failed to establish a likelihood of success on the merits because its asserted patent claims were likely invalid due to anticipation by the '394 patent, a prior art reference that disclosed all limitations of the claims. 2. Shockwave did not demonstrate a likelihood of success on the merits by showing a substantial question of patentability, as the prior art reference clearly anticipated the asserted claims. 3. The court held that Shockwave failed to demonstrate irreparable harm, as it did not show a sufficient causal nexus between the alleged infringement and the loss of market share or goodwill. 4. The court held that the balance of hardships did not tip in Shockwave's favor, noting that the potential harm to Cardiovascular Systems from an injunction outweighed the harm to Shockwave from its denial, especially given the likely invalidity of the asserted patent claims. 5. The court affirmed the district court's denial of a preliminary injunction, finding no abuse of discretion in its equitable balancing of the factors.

Q: What cases are related to Shockwave Medical, Inc. v. Cardiovascular Systems, Inc.?

Precedent cases cited or related to Shockwave Medical, Inc. v. Cardiovascular Systems, Inc.: Novelty, Inc. v. Focus Mgmt. Grp., Inc., 775 F.3d 1359 (Fed. Cir. 2015); Takeda Pharm. U.S.A., Inc. v. Watson Labs., Inc., 795 F.3d 1333 (Fed. Cir. 2015); Winter v. Nat. Res. Def. Council, Inc., 555 U.S. 7 (2008).

Q: What was the Federal Circuit's ultimate decision regarding the preliminary injunction?

The Federal Circuit affirmed the district court's denial of the preliminary injunction. The appellate court found that Shockwave Medical did not demonstrate a likelihood of success on the merits of its patent infringement claims, nor did it adequately show irreparable harm or that the balance of hardships favored an injunction.

Q: On what grounds did the Federal Circuit find Shockwave Medical unlikely to succeed on the merits?

The court found Shockwave's asserted patent claims likely invalid due to anticipation by a prior art reference, specifically a patent application by Dr. Bolger. This prior art reference was deemed to disclose all the elements of at least one of Shockwave's asserted claims.

Q: What is 'anticipation' in patent law, and how did it apply here?

Anticipation means that a prior art reference discloses every element of a claimed invention. In this case, the Federal Circuit determined that the Bolger prior art reference likely disclosed all the elements of Shockwave's asserted patent claims, meaning the invention was not new and therefore invalid.

Q: What legal standard does a party need to meet to obtain a preliminary injunction?

To obtain a preliminary injunction, a party must generally show (1) a likelihood of success on the merits, (2) that they are likely to suffer irreparable harm in the absence of preliminary relief, (3) that the balance of equities tips in their favor, and (4) that an injunction is in the public interest. Shockwave failed on the first two prongs.

Q: Did Shockwave Medical demonstrate a likelihood of irreparable harm?

No, Shockwave Medical failed to demonstrate a likelihood of irreparable harm. The Federal Circuit found that Shockwave did not provide sufficient evidence to show that it would suffer irreparable harm if the injunction were not granted, especially given the potential invalidity of its patent.

Q: How did the Federal Circuit analyze the 'balance of hardships' in this case?

The Federal Circuit concluded that the balance of hardships did not tip in Shockwave Medical's favor. Because Shockwave failed to show a likelihood of success on the merits and irreparable harm, the potential harm to CSI from being enjoined from selling its products outweighed any harm Shockwave might suffer.

Q: What is the significance of the 'abuse of discretion' standard on appeal?

The Federal Circuit reviews a district court's decision on a preliminary injunction for an abuse of discretion. This means the appellate court gives deference to the lower court's decision and will only overturn it if the district court made a clear error of judgment or applied the wrong legal standard.

Q: What is the role of prior art in patent validity?

Prior art refers to existing knowledge or inventions that predate a patent application. If a prior art reference discloses all the elements of a patent claim, that claim is considered 'anticipated' and therefore invalid because it was not novel when invented.

Q: What specific patent was at issue in Shockwave Medical v. Cardiovascular Systems?

The specific patent at issue was U.S. Patent No. 9,138,351, held by Shockwave Medical, Inc. This patent relates to intravascular lithotripsy technology used in medical procedures.

Q: What is intravascular lithotripsy (IVL)?

Intravascular lithotripsy (IVL) is a medical technology used to treat calcified lesions in arteries. It typically involves using sonic or electrical pulses delivered through a catheter to fracture calcium deposits, allowing for better blood flow restoration.

Q: How does Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. affect me?

This decision reinforces the high bar for obtaining preliminary injunctions in patent cases, particularly when the validity of the asserted patent is seriously challenged by clear prior art. It highlights that a strong showing of likely patent invalidity can be fatal to a preliminary injunction request, even if other factors might otherwise favor the patent holder. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: What are the practical implications of the Federal Circuit's decision for Shockwave Medical?

The decision means Shockwave Medical cannot stop Cardiovascular Systems, Inc. from selling its products through a preliminary injunction. Shockwave must continue to litigate the patent infringement case through trial, and the validity of its patent remains uncertain due to the prior art issue.

Q: How does this ruling affect Cardiovascular Systems, Inc. (CSI)?

For CSI, the ruling is a significant victory as it allows them to continue selling their products without the immediate threat of an injunction. However, CSI still faces the ongoing patent infringement lawsuit and the possibility of an injunction or damages if Shockwave prevails at trial.

Q: What is the potential impact on the market for IVL devices?

The denial of the injunction allows for continued competition in the IVL device market, at least in the short term. It means that patients and healthcare providers will continue to have access to CSI's products while the patent dispute is resolved, preventing a potential market disruption.

Q: What should companies in the medical device industry consider after this ruling?

Companies should be aware of the importance of thorough prior art searches and the potential for patent claims to be invalidated based on existing technology. They should also understand the high bar for obtaining preliminary injunctions in patent cases, particularly when patent validity is contested.

Q: Does this ruling mean Shockwave Medical's patent is definitely invalid?

No, the ruling does not definitively invalidate Shockwave Medical's patent. The Federal Circuit found the claims *likely* invalid based on the preliminary injunction standard. The ultimate validity of the patent will be determined through further proceedings, potentially including a full trial.

Q: How does this case relate to the evolution of patent law regarding preliminary injunctions?

This case exemplifies the ongoing tension in patent law between protecting patentees' rights and ensuring market competition. The Federal Circuit's rigorous application of the preliminary injunction standard, particularly the likelihood of success on the merits, reflects a consistent approach to prevent premature injunctions based on potentially invalid patents.

Q: Are there any landmark Federal Circuit cases that set precedents for preliminary injunctions in patent cases?

Yes, landmark cases like *Reebok Int'l Ltd. v. J. Baker, Inc.* and *Amazon.com, Inc. v. Barnesandnoble.com, Inc.* have shaped the standards for preliminary injunctions in patent law. The *Shockwave* decision continues to apply these established principles, emphasizing the importance of demonstrating a strong likelihood of patent validity and infringement.

Q: What was the docket number in Shockwave Medical, Inc. v. Cardiovascular Systems, Inc.?

The docket number for Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. is 23-1864. This identifier is used to track the case through the court system.

Q: Can Shockwave Medical, Inc. v. Cardiovascular Systems, Inc. be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: How did this case reach the Federal Circuit?

The case reached the Federal Circuit on appeal from a district court's order denying Shockwave Medical's motion for a preliminary injunction. Appeals of interlocutory orders, such as those granting or denying preliminary injunctions, are often heard by the Federal Circuit in patent cases.

Q: What is an interlocutory appeal?

An interlocutory appeal is an appeal of a ruling made by a trial court that is not a final judgment. In patent law, denials or grants of preliminary injunctions are often immediately appealable as interlocutory orders, allowing for appellate review before the entire case is concluded.

Q: What procedural steps led to the district court's denial of the injunction?

Shockwave Medical filed a lawsuit for patent infringement and moved for a preliminary injunction. The district court considered arguments and evidence from both sides, applied the four-factor test for preliminary injunctions, and ultimately denied the motion, finding Shockwave did not meet the required standards.